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Abstract
Prostate carcinoma is the most common cancer in men with few, quantifiable, biomarkers. Prostate cancer biomarker
discovery has been hampered due to subjective analysis of protein expression in tissue sections. An unbiased,
quantitative immunohistochemical approach provided here, for the diagnosis and stratification of prostate cancer
could overcome this problem. Antibodies against four proteins BTF3, HINT1, NDRG1 and ODC1 were used in a
prostate tissue array (> 500 individual tissue cores from 82 patients, 41 case pairs matched with one patient in each
pair had biochemical recurrence). Protein expression, quantified in an unbiased manner using an automated analysis
protocol in ImageJ software, was increased in malignant vs non-malignant prostate (by 2-2.5 fold, p<0.0001).
Operating characteristics indicate sensitivity in the range of 0.68 to 0.74; combination of markers in a logistic
regression model demonstrates further improvement in diagnostic power. Triple-labeled immunofluorescence (BTF3,
HINT1 and NDRG1) in tissue array showed a significant (p<0.02) change in co-localization coefficients for BTF3 and
NDRG1 co-expression in biochemical relapse vs non-relapse cancer epithelium. BTF3, HINT1, NDRG1 and ODC1
could be developed as epithelial specific biomarkers for tissue based diagnosis and stratification of prostate cancer.
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Introduction
Prostate carcinoma is a disease of the epithelium, the most
common cancer in men and the cause of considerable
morbidity and mortality [1]. Each year, over 30,000 men are
diagnosed of prostate cancer and over 10,000 die of the
disease in the UK. In 2010, 217,730 new cases of prostate
cancer were diagnosed in the US, with 32,050 American males
dying of the disease [2].
Diagnosis and prognosis of prostate cancer is based on
tissue morphology from biopsies (~1 million procedures in USA
and ~70,000 in the UK / year). First time biopsies identify
cancer in 38% of cases whereas equivocal diagnosis or false
negatives constitute ~25-30% of cases [3]. Descriptors of
aggressiveness (e.g. Gleason grade) determine cancer
management and therapy but have significant drawbacks and
high variance, particularly for low grade cancers.
Immunohistochemistry (IHC) is used in resolving equivocal
diagnosis, however, most IHC biomarkers have been identified
using subjective (scoring) analysis introducing large variability
[4]. For organ confined disease prostate biopsy remains a
critical clinical tool, however, there is a need to resolve false
negatives and refine diagnosis. By identifying cancers that
have good prognosis over-treatment could be reduced but
there are no quantitative protein markers to enhance the quality
of diagnosis. A reproducible, quantitative approach could
greatly facilitate this process.
Discovery of IHC markers, largely, and their analysis, is
conducted by semi quantitative approaches (e.g. scoring of
tissue sections stained with a chromo- or fluorophore) with
large inter-observer errors [4,5]. Scoring of the intensity of a
chromophore (or fluorophore) involves visual inspection
followed by a score within a predetermined range by the
experimenter. An approach based upon visual observation of
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patterned objects like mammalian tissue, with distinct
architecture, or visual assesment of intensity of a light signal as
done for IHC scoring, entails with severe limitations of
perception of illuminance and judgment, generally [6] and for
assessment of prostate carcinoma, specifically [7]. A further
disadvantage of using a subjective scoring approach is that the
selection of target proteins to be investigated gravitates
towards the extremes (either highly expressed in cancer (e.g.
EZH) or absent in cancer (e.g. cytokeratins 5 and 6). This
means that a large number of significant biological changes
that inevitably occur within these extremes are not picked up
and cannot be used for the understanding of the mechanisms
of carcinogenesis or developed as biomarkers for diagnosis, or
stratification or prognosis of cancer. Quantitative IHC [8] can
identify novel biomarkers in an unbiased, reproducible manner,
and in conjunction with fluorescent probes could be useful for
the latter. It is likely that not only the expression but co-
localization of two or more proteins may also change as a
result of disease or treatment [9,10]. A pre-requisite for
prognosis of the disease based upon molecular, rather than
morphological, criteria also requires robust and reproducible
detection of protein expression in IHC sections that could be
followed by quantifying co-localization changes in
immunofluorescence [10].
In a previous study we developed a semi-automated,
quantitative method to measure the expression of Wnt5A in
prostate tissue [8] in a prostate tissue array (> 500 tissue cores
from 82 patients, 41 case pairs matched with one patient in
each pair had biochemical recurrence). The aim of this study
was to employ the quantitative IHC approach to assess if this
method could be used to identify putative cancer markers for
diagnostic purposes. We chose four genes BTF3, NDRG1,
HINT1 and ODC1 that are up-regulated in prostate carcinoma
(oncomine.org; selection criteria: p=0.0001, 2 fold change and
in top 10% of genes over-expressed in the overall dataset) in at
least four normal vs cancer prostate gene expression analysis
datasets [11–14]. We used quantitative immunohistochemistry
[8] to show that the expression of BTF3, HINT1, NDRG1 and
ODC1 proteins is increased in prostate cancer tissue and could
serve as putative targets for the investigation of carcinogenesis
or biomarkers for disease. We then employed a quantitative
immunofluorescence approach to stratify prostate cancer using
co-localization coefficients of BTF3, HINT1 and NDRG1.
Results
Quantitative immunohistochemical analysis of proteins
over-expressed in prostate cancer tissue
Expression of BTF3, HINT1, NDRG1 and ODC1 was largely
epithelial and increased in malignant compared to benign or
non-malignant prostate cores (Figure 1). We quantified the
grayscale DAB-label (Figure 1 and Figure S1), in an unbiased
manner, by using a reproducible, semi-automated particle
analysis (Analyze Particles) protocol [8] using grayscale
images of the stained tissue from over 450-500 individual
prostate tissue cores for each biomarker (Figure 2).
Calculations of total area and area fraction are given in Table
1. Integration of AUC revealed an increase in the expression of
BTF3, HINT1, NDRG1 and ODC1 in malignant cores,
diagnosed by histopathology, compared to non-malignant
cores (p<0.0001, Mann Whitney U test). These results identify
BTF3, HINT1, NDRG1 and ODC1 as proteins that are over-
expressed in prostate cancer.
To investigate the utility of the proteins as putative
biomarkers for prostate cancer diagnosis, we calculated the
true positive rate (sensitivity) and false positive rate (1-
specificity) by ROC curve (Figure 3). The area fraction data
was transformed into probit and fitted to a Gaussian function.
AUC values of 1.0 for an ROC curve represent high selectivity
and sensitivity, whereas 0.5 suggests that the tested marker
cannot distinguish between non-malignant and malignant
categories. The dot plots of the transformed data are given in
Figure 1.  DAB-HRP tissue staining for BTF3, HINT1,
NDRG1 and ODC1 in representative malignant (A,C,E,G)
and non-malignant (B,D,F,H) prostate tissue cores.  (of over
500 tissue cores stained for each antibody) from human
prostate arrays. These are representatives of over 450-500
tissue core images analyzed for each biomarker antibody using
the automated image analysis protocol (see Materials and
Methods – Image particle analysis). Each core was imaged
using a Leica upright microscope (10x) and saved as a jpg file.
Each image was used to calculate protein expression (DAB
label, brown, largely in acinar cells). Colored RGB images (A-
H) were converted to corresponding grayscale images (I-P) for
the quantification of the DAB signal using Analyze Particle
protocol in ImageJ software to obtain Total Area stained, in
pixel. Protein expression for BTF3, HINT1, NDRG1 and ODC1
was increased in malignant v benign cores (p<0.0001).
doi: 10.1371/journal.pone.0084295.g001
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Figure S2. Sensitivity and 1-specificity were calculated for the
area fraction values for NDRG1, BTF3, HINT1 and ODC1
(Table S1). Fixed threshold (criteria >) values for putative
biomarkers for diagnosis range between 0.68 and 0.74 (Table
S1), indicating high sensitivity for NDRG1, BTF3 and HINT1, as
diagnostic markers for identifying prostate cancer in tissue
cores by unbiased, quantitative immunohistochemistry. Positive
likelihood ratios (LR+) for each biomarker at the designated
criteria (Table S1) ranged from 1.7 to 2.4. A likelihood ratio of
greater than 1 indicates that the result is associated with the
presence of disease [15]. NDRG1, BTF3 and HINT1 also
showed LR+ of >10 at various criteria cut off points; LR+s
above 10, for a diagnostic test, are considered to provide
strong evidence to rule in disease [15,16] . The diagnostic
power was further enhanced by incorporating data from two
biomarkers into a logistic regression model (Table 2). Gleason
grades 4+3 and 3+4 made up >80% of the malignant tissue
samples arrayed on the tissue array (between 221-241 tissue
cores, see Table S2). There was no significant difference in
expression of the four biomarkers when segregated for
analysis based upon Gleason grade (4+3 and 3+4; Figure S3).
Figure 2.  Quantitation of DAB signal in prostate tissue
array.  An unbiased, automated protocol was used to calculate
Total Area stained (in pixel) standardized to amount of tissue in
each core (see Methods). TA is converted to Area Fraction
(total area divided by the total pixels in the image). Each bin is
data for an individual, malignant (red) or non-malignant tissue
(green) core. There is a significant increase in the AUC of
protein expression in malignant v non-malignant prostate tissue
(p<0.0001).
doi: 10.1371/journal.pone.0084295.g002
Disease stratification using multiple markers and
immunofluorescence staining
It is estimated that around 30% of patients undergoing
radical prostatectomy for clinically localized disease will
experience biochemical relapse (defined as detectable PSA ≥
0.2 ng ml-1 within 2 years of surgery). A cohort of patients used
for the tissue array in this study, had undergone biochemical
relapse [17]. We hypothesized that not only a change in
expression but also co-localization of the identified biomarkers
changes in prostate cancer epithelium. This was investigated
by multi-labeled immunofluorescence staining using BTF3,
HINT1 and NDRG1 antibodies (Figure 4). The 3 proteins were
differentially expressed in non-malignant (Figure 4A) compared
to malignant (Figure 4B) cores and found to be largely in the
prostate epithelium, confirming the data from individual
antibodies staining using 3,3-diaminobenzidine-horse radish
peroxidase (DAB-HRP, Figure S1 and Figure 1). These results
indicate not only that the expression of these protein
biomarkers, individually, is increased in prostate cancer (Figure
2) but that the expression is largely epithelial and thus specific
to the disease process (Figure 4).
The co-localization of BTF3, HINT1 and NDRG1 was next
investigated in the multi-labeled immunofluorescence tissue
cores from relapsed and non-relapsed patients from composite
fluorescent images (Figure 5; BTF3, HINT1 and NDRG1,
green, blue and red, respectively) in order determine the utility
of this approach for prostate cancer stratification. There is an
evident and quantifiable change in the pattern of staining of
these protein biomarkers in biochemical relapse tissue cores:
Table 1. Quantitation of protein expression in malignant
and non-malignant human prostate tissue arryas using
ImageJ software.
Protein Condition (n) Total Area Area Fraction* Fold increase
BTF3 Benign (236) 22301 ± 1697 1.66 ± 0.12  
 Malignant (228) 54750 ± 3588 4.09 ± 0.27 2.5
HINT1 Benign (214) 28564 ± 1882 2.13 ± 0.14  
 Malignant (225) 67173 ± 3977 4.93 ± 0.29 2.3
NDRG1 Benign (230) 27752 ± 1875 2.07 ± 0.14  
 Malignant (223) 72297 ± 4380 5.4 ± 0.33 2.6
ODC1 Benign (261) 38621 ± 4184 2.80 ± 0.31  
 Malignant (243) 65428 ± 5389 4.88 ± 0.4 1.8
DAB label, representing protein expression for BTF3, HINT1, NDRG1 and ODC1
was quantified in an unbiased manner, by using a reproducible, semi-automated
particle analysis (Analyze Particles) protocol with ImageJ software. Over 500
individual prostate tissue cores (see methods) RGB images were converted into 16
bit grayscale. The results are means ± SE for the calculated parameters of total
area and area fraction. These data are standardized for amount of tissue on each
core by using the inverse protocol on ImageJ (see methods). Fold increase in the
expression of protein in malignant compared to non-malignant (benign) cores was
confirmed by AUC calculations of data from Figure 2. (n)= number of usable cores
included in the analysis. *Statistical analysis: expression, for all proteins, is
significantly different in malignant compared to non-malignant prostate at
P<0.0001 using Mann Whitney U test.
doi: 10.1371/journal.pone.0084295.t001
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BTF3 expression appears less in relapsed, compared to non-
relapsed samples, whereas HINT1 and NDRG1 expression
appears dominant in relapsed tissue samples (representative
tissue cores from biochemical relapse and control patients are
shown in Figure 5A and B); quantitative colocalization analysis
Figure 3.  ROC of putative prostate cancer
biomarkers.  ROC curve demonstrates the discriminating
performance of the protein expression in the differentiation
between malignant and non-malignant tissue cores using the
area fraction (probit) data for BTF3, HINT1, NDRG1 and
ODC1. The operating characteristic values are given in Table
S1. The solid line represents the ROC area of 0.5.
doi: 10.1371/journal.pone.0084295.g003
Table 2. Logistic regression model to identify combination
of markers that may improve diagnostic power.
Protein combination % cases correctly identfied*
BTF 3 and HINT1 72   
BTF3 and NDRG1 78   
BTF3 and ODC1 93   
HINT1 and NDRG1 81   
HINT1 and ODC1 85   
NDRG1 and ODC1 97   
A logistic regression model was employed using MedCalc software to analyze the
relationship between one dichotomous dependent variable (non-malignant v
malignant) and one or more independent variables (two biomarkers). The outcome
(percentage of cases correctly identified) suggests that within the cohort of
samples used in this study, the diagnostic power to identify malignant cases is
increased with the combination of BTF3 and ODC1 and NDRG1 and ODC1. *The
significance level of the overall model fit for the analysis for all combinations is
p<0.0001.
doi: 10.1371/journal.pone.0084295.t002
of high magnification deconvoluted images (Figure 5C and D)
showed that most of the apparent change in the pattern of
expression, for multi-labeled tissue sections in non-relapsed vs
relapsed samples, was due to the change in co-expression of
BTF3 (fluorescein isothiocyanate, FITC, green) and HINT1
(cyanin 3, Cy3, blue). Calculated Pearson coefficients for
colocalization for non-relapse vs relapse were 0.73 ± 0.02 vs
0.60 ± 0.07 (means ± SD, n=4 , significance of difference
p<0.02). Quantitative co-localization indicates that multi-
labeling approach could be used for the stratification of
prostate cancer in tissue cores.
Discussion
By using global gene expression analysis, tremendous
progress has been made in the identification of dysregulated
genes in prostate cancer over the past decade. What has been
lacking is the translation of these genes into clinically useful
biomarkers for the diagnosis and stratification of the disease.
Human prostate was one of the first tissues to be investigated
for global changes in gene-expression in disease almost a
decade ago. Incidentally, the approval of new markers by Food
and Drug Administration, USA, particularly protein markers,
has declined over the past decade. This decline could be
attributed to three major problems in the identification and
development of tissue based protein biomarkers for the
diagnosis and prognosis of prostate cancer: 1. Lack of
specificity, ie not epithelium specific (the site of initiation of the
disease) 2. Lack of an unbiased, automated, quantitative
analysis of protein expression that could identify robust,
reprdoucible data for putative biomarkers 3. Lack of
quantitative, proteomic approaches to for a molecular basis of
prostate cancer prognosis.
Immunohistochemical markers could be extremely useful in
primary or confirmatory diagnosis in support of histopathology,
but due to the difficulties in identification or validation [18] only
a handful of such markers exist. It also appears likely that
histopathological analysis will remain a bulwark for prostate
cancer diagnosis in the near to medium future. Thus in addition
to continuing search for the identification of non-invasive
biomarkers that could be detected in bodily fluids, it is
important to keep refining and improving the immunochemical
tissue biomarkers that could facilitate diagnosis, improve
prognosis and provide useful predictive stratification of prostate
cancer. Due to the increase in computing power over the last
decade two technologies have matured that could help achieve
these objectives. These are discussed below.
Morphological analysis is routinely used to diagnose prostate
cancer, although IHC is used to assist morphological diagnosis,
particularly in equivocal cases, e.g. in tissue samples from
needle biopsies, transurethral resection specimens and
metastatic tumor samples [19]. A complicating issue hindering
discovery of new biomarkers for diagnosis and disease
stratification of prostate (and other) cancer(s) from biopsy
samples, has been a dearth of unbiased, quantitative methods
to detect significant changes from IHC experiments for
biomarker identification. There are, however, some exceptions
to this approach. Rubin and colleagues [20] devised a
Biomarkers of Prostate Cancer
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Figure 4.  Multi-labeled immunofluorescence for BTF3, HINT1 and NDRG1.  Co-expression of three proteins BTF3 (FITC-
green), HINT1 (Cy3- blue) and NDRG1 (Cy5-red) in non-malignant (A) and malignant prostate tissue cores (B); images are
representative tissue cores from the tissue array with over 200 samples. The three antibodies were incubated simultaneously and
labeled with three Cy5 –red different fluorophores using Bond automated staining system. Whole tissue cores were imaged using a
Leica confocal system and 4x4 tiling at exactly the same settings for comparison. Images were zoomed 3x using digital zoom in
ImageJ. Scale bar =100µm.
doi: 10.1371/journal.pone.0084295.g004
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Figure 5.  Differential pattern for BTF3, HINT1 and NDRG1
co-expression in malignant, biochemical relapse and non-
relapse sample.  Co-expression of three proteins BTF3 (FITC-
green), HINT1 (Cy3- blue) and NDRG1 (Cy5 –red) in malignant
prostate tissue cores (A to D). Composite micrographs of
immunofluorescently stained prostate tissue cores from
patients with biochemical relapse (defined as PSA ≥ 0.2 ng/ml
within 2 years of radical prostatectomy). Tissue cores from 4
patients (matched pairs for Gleason score and PSA), non-
relapsed (A) and biochemical relapse (B) representative
images used for quantitative co-localization analysis (see
methods) are shown. Imaging was performed using a Leica
confocal microscope; A and B are low magnification; C and D
higher magnification; E is an example of the expression of the
three markers in non-malignant tissue also at higher
magnification. The expression of BTF3 (green), for example is
evident in non-relapsed samples whereas it not very evident in
cores from relapsed patients. Imaging was performed using an
Olympus confocal microscope (40x tiled (A and B) or 40x with
digital zoom 3.5-4 (C, D and E). High magnification images
(C,D and E) were deconvolved using Huygens Profession
software. 16bit tif files for each fluorophore (FITC, Cy3 and
Cy5) were imported into ImageJ and pseudo colored (FITC,
green, Cy3, blue and Cy5, red). Z-projections for up to 27
images are shown for each tissue core. Scale bar =100µm for
A and B and 20µm for C and D. Quantitative colocalization
analysis of images (e.g. Figure 5C and D) showed that most
significant change in the pattern of expression, in non-relapsed
vs relapsed samples, was due to the change in co-expression
of BTF3 (FITC, green) and HINT1 (Cy3, blue) with Pearson
coefficients for colocalization for non-relapse vs relapse = 0.73
± 0.02 vs 0.60 ± 0.07 (means ± SD, n=4 , significance of
difference p<0.02).
doi: 10.1371/journal.pone.0084295.g005
quantitative approach to identify α-methylacyl-CoA racemase
(AMACR). Initial studies showed almost uniform expression of
this protein in cancerous tissue but in later analysis the
expression was found to be less and, with reservation, this
protein is used as a diagnostic marker.
To address the issue of bias and reliance on subjective
assessment of expression of a given biomarker, we developed
a method, free of experimenter bias, to quantify protein
expression in prostate cancer [8] using a freely available
software [21]. Unlike the conventional, scoring methods (e.g. of
DAB staining) to estimate expression in tissue arrays, our
approach allows unbiased quantitation of the total DAB signal.
Although quantifying total DAB signal may not be ideal, by
standardizing signal measurement and eliminating arbitrary
scoring we identified BTF3, NDRG1, HINT1 and ODC1 protein
levels to be over-expressed in prostate carcinoma, quantifiably
and reproducibly, confirming the gene over-expression
observed from our preliminary gene list. Operating
characteristics (Figure 3 and Table S1) for BTF3, HINT1 and
NDRG1 show AUC of 0.71 to 0.76; an AUC of >0.7 is
considered acceptable for a diagnostic marker [22] indicating
that, individually, these are adequate biomarkers of disease.
The diagnostic power may be further enhanced when these
markers are analyzed for aggregated diagnostic power (Table
2). Furthermore, BTF3, NDRG1 and HINT1, in quantitative co-
localization studies (Figure 5) appear capable of discriminating
between biochemical relapse and non-relapse prostate cancer.
The biomarkers identified here are novel for their use in
diagnosis and also in the combinations described for
biochemical relapse of prostate cancer. The possible
mechanisms by which these putative prostate carcinoma
biomarkers may contribute to carcinogenesis are discussed
below.
BTF3 is a 27kDa protein that forms a stable complex with
RNA polymerase IIB and is required for transcriptional initiation
[23] and known to be over-expressed in cells from pancreatic
ductal carcinoma both in vitro and in situ [24]. NDRG1
(previously known as Cap43), a stress response gene, has
been implicated in various cellular processes in health and
disease. Unlike the expression of other biomarkers presented
here, the expression of NDRG1 has been investigated in
prostate tissue but is a subject of controversy with reports that
it is increased [25] and decreased [26] in prostate cancer. It is
important to note however that none of these studies employed
an unbiased quantitative technique and therefore the
expression analysis may be the reason for these
discrepancies.
We have previously shown that Wnt signaling pathway plays
an important role prostate cancer [8,27] . NDRG1 has also
been shown to influence Wnt signaling and there is a prima
facie case for the involvement of NDRG1 in the regulation of
Wnt signaling in prostate cancer cell lines [28]. NDRG1 gene is
also an ETS-family fusion partner in ERG-expressing prostate
cancer but unlike TMPRSS2-ERG and SCL45A3-ERG fusions,
prevalent in prostate cancers, the NDRG1-ERG fusion is
thought to encode for a chimeric protein [29]. No information
exists regarding NDRG1 protein expression in prostate cancer;
Biomarkers of Prostate Cancer
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whether found to be fused to ERG or not, NDRG1 could be a
useful protein biomarker for prostate cancer.
HINT1 belongs to the histidine triad (HIT) family and a
protein kinase C interacting protein [30]. No information exists
on HINT1 expression or function in prostate cancer although it
may act as tumor suppressor in mice [31]. In a hepatoma cell
line, HINT1 inhibits activity of Wnt/ß-catenin signaling and gene
transcription via TCF4 [32]. We have shown, previously, that
there is a suppression of ß-catenin/TCF4 mediated gene
transcription of TCF4 transcription targets [8]. It is tempting to
speculate that HINT1 may contribute towards the inhibition of
Wnt/ß-catenin signaling in prostate cancer [8].
L-Ornithine decarboxylase 1 (ODC1) is an enzyme in the
polyamine synthesis pathway [33] a key factor in normal cell
proliferation and neoplastic growth. ODC1 has been identified
as a genetic marker for colon cancer [34] and over-expression
of ODC1 has been linked to high risk neuroblastomas [35] and
colorectal and breast cancers [36]. These data correlate to in
vivo experiments with ODC1 knock-out mice which developed
fewer tumors in response to various carcinogenic promoters in
line with the reduced gene copy number [37].
Our data suggests that using an unbiased, quantitative
approach to identify epithelium specific biomarkers in
combination with immunofluorescence could prove useful in
diagnosis, stratification and prognosis of prostate carcinoma.
Materials and Methods
Prostate tissue array
Patient selection, disease state and construction details of
tissue blocks are given elsewhere [8,17]. Briefly, tissue blocks
were constructed using archival formalin-fixed, paraffin-
embedded radical prostatectomy specimens from the 82
patients with pathological stage pT3a or b and pre-operative
PSA stage of >3. 41 case pairs were matched for the following
categories: pathological stage, Gleason grade and
preoperative prostate-specific antigen (PSA) concentration.
One patient in each pair had biochemical recurrence (defined
as PSA ≥ 0.2 ng mL-1 within 2 years of surgery) and the other
remained biochemically free of disease (defined as
undetectable PSA at least 3 years after surgery). The cores
were diagnosed (as benign or non-malignant and malignant)
and marked by a pathologist and 5-6μm sections were cut from
the tissue arrays onto coated slides. To eliminate bias, the
experimenters were blind to staining, imaging and analysis,
with the latter being automated (see below). Clinical details of
the tissue samples used are given in Table S2 and [17];
pathologists scored a majority of samples (>80%) as Gleason
grade 4+3 and 3+4. A sample size calculation was made for
differentiating between over-expression using DAB-IHC; the
sample size for the protein expression was calculated prior to
the construction of the tissue array (with an α and ß of 0.05 and
expected difference of 2.5 folds between the means of
malignant and non-malignant samples to be 41 patients per
group).
Ethics approval
Ethical approval was given by the Joint UCL/UCLH
committees on the ethics of human research. The review board
(RB) approved the use of human tissue for prostate cancer
research, in compliance with the International Committee on
Harmonization of Good Clinical Practice (ICH GCP). For tissue
array construction the samples were anonymized during the
construction of the tissue arrays [17] and used for various
immunohistochemical studies in a project approved by the
UCL/UCLH ethics committee. The RB waived the need for
informed consent because the samples used for tissue array
were archival pathological samples.
3,3-diaminobenzidine-horse radish peroxidase(DAB-
HRP) staining
All staining was performed using Bond automated system [8]
according to manufacturer’s protocols. Details of the staining
procedure for IHC using DAB and antibodies (BTF3, HINT1,
NDRG1 and ODC1) used are given in Methods S1.
Immunofluorescence staining using 3 antibodies in
prostate tissue arrays
The protocol for immunofluorescence staining was similar to
that described for DAB staining, above, except that BTF3,
HINT1 and NDRG1 antibodies incubated simultaneously and
stained with FITC, Cy5 and Cy3 respectively, according to
manufacturer’s protocol. Images were acquired using a Leica
710 confocal microscope with an EC Plan-Neofluar (40x)
objective.
Image particle analysis using ImageJ software
An unbiased, reproducible, automated particle analysis
method [8] was employed to quantify the DAB signal on non-
malignant (benign) and malignant human prostate tissue cores
using ImageJ software [21]. Macros were written to execute the
following sequence of events for acquired jpeg images: 1.
Open image 2. Convert to 16-bit image 3. Set threshold 4.
Analyze particle (Size 0.5- Infinity, Circularity 0.00-1.00) 5.
Save image 6. Save particle information (count, total area,
average size and area fraction) into an excel spreadsheet
(rsb.info.nih.gov/ij/docs/pdfs/examples.pdf). Units are default
ImageJ setting (pixels). Standardization for the amount of
tissue per core was also quantified by using the inverse
function (EditInvert image) in ImageJ with the protocol
described above. Quantified DAB signal is expressed as
signal / amount of tissue in each tissue core. A flow chart for
DAB signal quantitation is given in Figure S1. For all antibodies
tested, expression was observed to be largely epithelial and
analysis was also restricted to the epithelial expression; set
threshold parameters were chosen after manual analysis of
random cores for the subsequent quantitation of the signal. A
contiguous spreadsheet for all the usable cores (between 211
and 260 cores) for non-malignant vs malignant comparison, for
different antibodies was constructed. Tests for normal
distribution (Kolmogorov-Smirnov test) of the acquired data and
subsequent statistical tests for significance of difference
between protein expression in malignant and non-malignant
Biomarkers of Prostate Cancer
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cores was conducted using Mann Whitney U test. Mountain
plots were constructed and analyzed for area under the curve
(AUC) using Origin (Microcal). Receiver Operating
Characteristics (ROC) curves were constructed after converting
the data to normal distribution using probit using MedCalc
software; likelihood ratios were also calculated from the ROC
curves using MedCalc software.
For quantitative colocalization of BTF3, HINT1 and NDRG1
tissue cores were imaged using an Olympus IX81 confocal
system using a dry 40x objective (3.5 to 4x digital zoom). The
‘oif’ files were imported into Huygens Professional software for
image deconvolution. The deconvolved images were saved as
16bit TIFF files for each channel (excitation/emission (nm)
FITC = 488 / 519, Cy3 = 559 / 567, Cy5 = 635 / 664). The 16bit
TIFF files were imported into ImageJ and the colocalization
plugin (Wright Cell Imaging Facility, University of Toronto) used
to calculate Pearson co-efficient for colocalization.
Supporting Information
Figure S1.  Schematic representation of the process to
calculate DAB signal and amount of tissue per sample
(core) using ImageJ particle analysis protocol. The DAB
stained image (A) is converted to a grayscale image (B). For
DAB signal calculation (C) a threshold is applied and the
particles quantified. To calculate the amount of tissue, the
grayscale image is inverted (D) and particles calculated.
(TIF)
Figure S2.  Dot plots of area fraction values for BTF3,
HINT1, NDRG1 and ODC1 used to obtain operating
characteristics (Figure 4). N-M = non-malignant and M =
malignant prostate tissue cores.
(TIF)
Figure S3.  Malignant prostate tissue cores (221-241) were
analyzed on for protein expression (area fraction (AF) /
amount of tissue) based upon the Gleason grade. Majority
(>80%) of the malignant tissue cores were graded 4+3 and
3+4. A comparison between these two Gleason grades did not
show a significant difference for the expression of four
biomarkers tested (Mann-Whitney test). Data is presented as
means ± SEM for 75-109 individual tissue cores for each grade
for the four biomarkers.
(TIF)
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